MediWound Ltd.

NasdaqGM:MDWD Stock Report

Market Cap: US$192.1m

MediWound Management

Management criteria checks 2/4

MediWound's CEO is Ofer Gonen, appointed in Jun 2022, has a tenure of 2.58 years. total yearly compensation is $1.13M, comprised of 42.4% salary and 57.6% bonuses, including company stock and options. directly owns 1.04% of the company’s shares, worth $1.99M. The average tenure of the management team and the board of directors is 2 years and 2.4 years respectively.

Key information

Ofer Gonen

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage42.4%
CEO tenure2.6yrs
CEO ownership1.0%
Management average tenure2yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Are Trimming Their Forecasts

Nov 29
Earnings Update: MediWound Ltd. (NASDAQ:MDWD) Just Reported And Analysts Are Trimming Their Forecasts

MediWound Is A Healthy Investment

Oct 29

Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

Jul 23
Market Participants Recognise MediWound Ltd.'s (NASDAQ:MDWD) Revenues Pushing Shares 43% Higher

Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

Jun 01
Analysts Have Made A Financial Statement On MediWound Ltd.'s (NASDAQ:MDWD) First-Quarter Report

Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%

May 07
Revenues Tell The Story For MediWound Ltd. (NASDAQ:MDWD) As Its Stock Soars 25%

We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely

Feb 28
We're Hopeful That MediWound (NASDAQ:MDWD) Will Use Its Cash Wisely

Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking

Feb 01
Optimistic Investors Push MediWound Ltd. (NASDAQ:MDWD) Shares Up 26% But Growth Is Lacking

MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up

Dec 18
MediWound Ltd.'s (NASDAQ:MDWD) 26% Share Price Surge Not Quite Adding Up

MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

Sep 29
MediWound Ltd. (NASDAQ:MDWD) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected

MediWound's NexoBrid for thermal burns in children gets EMA review

Sep 20

Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates

Aug 11
Need To Know: Analysts Just Made A Substantial Cut To Their MediWound Ltd. (NASDAQ:MDWD) Estimates

MediWound GAAP EPS of -$0.13 misses by $0.03, revenue of $4.67M misses by $0.61M

Aug 09

MediWound refiling for NexoBrid to treat severe thermal burns gets FDA review

Aug 03

MediWound adds 13% after favorable data for ulcer candidate

Jul 07

MediWound taps Tzvi Palash as COO

Jun 30

Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?

Jun 24
Is MediWound (NASDAQ:MDWD) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching MediWound's (NASDAQ:MDWD) Cash Burn Situation

Dec 07
Here's Why We're Watching MediWound's (NASDAQ:MDWD) Cash Burn Situation

MediWound: Adjusting My Strategy After NexoBrid CRL

Jul 28

CEO Compensation Analysis

How has Ofer Gonen's remuneration changed compared to MediWound's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$28m

Jun 30 2024n/an/a

-US$20m

Mar 31 2024n/an/a

-US$13m

Dec 31 2023US$1mUS$480k

-US$7m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$20m

Dec 31 2022US$850kUS$253k

-US$20m

Compensation vs Market: Ofer's total compensation ($USD1.13M) is about average for companies of similar size in the US market ($USD1.38M).

Compensation vs Earnings: Ofer's compensation has increased whilst the company is unprofitable.

CEO

Ofer Gonen (51 yo)

2.6yrs

Tenure

US$1,133,000

Compensation

Mr. Ofer Gonen, B.Sc. MA Economic & Finance, serves as Chief Executive Officer at MediWound Ltd. since June 30, 2022. He was Chief Executive Officer of Clal Biotechnology Industries Ltd.from March 7, 2017...

Leadership Team

NamePositionTenureCompensationOwnership
Ofer Gonen
Chief Executive Officer2.6yrsUS$1.13m1.04%
$ 2.0m
Hani Luxenburg
Chief Financial Officer1.7yrsUS$244.00kno data
Yaron Meyer
Executive VP11.1yrsUS$379.00kno data
Ety Klinger
Chief Research & Development Officer10.7yrsUS$479.00kno data
Lior Rosenberg
Co-Founder24yrsUS$817.00kno data
Shmulik Hess
COO & Chief Commercial Officer1.1yrsno datano data
Liron Gal
Executive Director of Manufacturing Science & Technologyless than a yearno datano data
Barry Wolfenson
Executive Vice President of Strategy & Corporate Development1.8yrsno datano data
Robert Snyder
Chief Medical Officer2yrsno datano data

2.0yrs

Average Tenure

54yo

Average Age

Experienced Management: MDWD's management team is considered experienced (2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Stephen Wills
Independent Director7.7yrsno datano data
Nachum Shamir
Executive Independent Chairman2.4yrsno datano data
David Fox
Independent Director4.8yrsno datano data
Vickie Driver
Independent Director7.7yrsno datano data
Samuel Moed
Member of Strategic Advisory Board2.3yrsno datano data
Samuel Rubinstein
Independent Director1.4yrsno datano data
John Lantis
Member of Strategic Advisory Board2.3yrsno datano data

2.4yrs

Average Tenure

70yo

Average Age

Experienced Board: MDWD's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 03:25
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MediWound Ltd. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David MarisBMO Capital Markets Equity Research
Jason WittesBrean Capital
Michael GormanBTIG